Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech’s AI Pioneers – Where Are We Headed?

Executive Summary

Artificial intelligence (AI) is quickly becoming part of our day-to-day routines, and healthcare is one area in which AI stands to make the biggest impact. But where is the technology headed? Leading figures from the medtech industry gathered at the Medical Design & Manufacturing East (MD&M East) meeting held in New York City to discuss.

You may also be interested in...



MTI Outlook 2020: Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. AI is now increasingly seen as a realistic solution to demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.  

Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

FDA: Apple De Novo Approvals Signal Innovation To Digital Health Firms

The latest Apple Watch includes an electrocardiogram that has received de novo clearance from US FDA to detect irregular heart rhythms. The approval, say two top US FDA regulators, is a signal to the digital health industry that the agency is trying to help them innovate.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT125277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel